Status:

COMPLETED

RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

Lead Sponsor:

Merck Sharp & Dohme LLC

Conditions:

Meningitis, Meningococcal

Rotavirus Infections

Eligibility:

All Genders

42-55 years

Phase:

PHASE3

Brief Summary

Primary objective: To check if RotaTeq® can be administered concomitantly with meningococcal Group C vaccine without impairing the efficacy of MCC vaccine. The hypothesis tested is that the seroprote...

Eligibility Criteria

Inclusion

  • Healthy infants, aged from 6 weeks through full 7 weeks,
  • Consent form signed by at least one parent or by the legal representative properly informed about the study,
  • Parent(s) / legal representative able to understand the protocol requirements and to fill in the Diary Card.

Exclusion

  • History of congenital abdominal disorders, congenital malformation of the gastrointestinal tract that could predispose to intussusception, or abdominal surgery,
  • Congenital fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency,
  • Known or suspected impairment of immunological function,
  • Known hypersensitivity to any component of RotaTeq® (e.g. sucrose) or of NeisVac-C® (including tetanus toxoid),
  • Prior administration of any rotavirus vaccine,
  • Prior administration of any vaccine within the 28 days prior to randomisation,
  • Fever (rectal temperature ≥38.1°C) and/or acute diarrhoea and/or vomiting at randomisation,
  • History of known prior rotavirus gastroenteritis, chronic diarrhoea, or failure to thrive,
  • Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection,
  • Clinical evidence of active gastrointestinal illness,
  • Receipt of intramuscular, oral, or intravenous corticosteroid treatment within the 14 days prior to randomisation. Note: Infants on inhaled and/or topical steroids may participate in the study,
  • Infants residing in a household with an immunocompromised person,
  • Prior receipt of a blood transfusion or blood products, including immunoglobulins.

Key Trial Info

Start Date :

February 13 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 23 2007

Estimated Enrollment :

247 Patients enrolled

Trial Details

Trial ID

NCT00443846

Start Date

February 13 2007

End Date

October 23 2007

Last Update

June 20 2018

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016) | DecenTrialz